Novartis’ chairman Daniel Vasella was elected board chairman of Alcon, increasing the Swiss drugmaker’s grip of the U.S. eyecare company as it tries to buy the stake it does not already own. Alcon’s Independent Director’s Committee (IDC), which has r…
Category: Business
Report on global ophthalmology drug and devices market
Global ophthalmology drug and devices market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. With …
Time is on Novartis Side in Alcon Bid
Novartiss bet that with time it would win over Alcon Inc.s shareholders seems to be paying off. Since the Swiss pharma giant bought a majority stake in the eye-care firm earlier this year, resistance from Alcons minority shareholders to Novartiss off…